ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

KRBP Kiromic BioPharma Inc

0.60
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Kiromic BioPharma Inc NASDAQ:KRBP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.60 0.5315 0.6675 0 01:00:00

KRBP SHAREHOLDER ALERT: Jakubowitz Law Reminds Kiromic Shareholders of a Lead Plaintiff Deadline of October 4, 2022

09/09/2022 10:45am

PR Newswire (US)


Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart


From Apr 2022 to Apr 2024

Click Here for more Kiromic BioPharma Charts.

NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/kiromic-biopharma-inc-loss-submission-form/?id=31462&from=4

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until October 4, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the "Offering Documents") failed to disclose that the Food and Drug Administration ("FDA") had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ("IND") applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

Cision View original content:https://www.prnewswire.com/news-releases/krbp-shareholder-alert-jakubowitz-law-reminds-kiromic-shareholders-of-a-lead-plaintiff-deadline-of-october-4-2022-301620865.html

SOURCE Jakubowitz Law

Copyright 2022 PR Newswire

1 Year Kiromic BioPharma Chart

1 Year Kiromic BioPharma Chart

1 Month Kiromic BioPharma Chart

1 Month Kiromic BioPharma Chart

Your Recent History

Delayed Upgrade Clock